Read More Pharma Industry News Rezolute shares plunge after Phase 3 sunRIZE study fails to show significant benefit in congenital hyperinsulinism Rezolute shares collapsed after its Phase 3 sunRIZE trial failed in congenital hyperinsulinism. Find out what went wrong and what it means for investors now. bySoujanya RaviDecember 13, 2025